One possible candidate for a downstream target of HER-2 was the PI3K–AKT pathway, based on previous analyses in other tumour types (Knuefermann et al, 2003; Qi et al, 2009); hence, we focused on this pathway. Here, ERBB2 is linked to neoplasm.